Aim: To design and evaluate the transdermal drug delivery system with low dose of felodipine. Objective: To develop matrix type transdermal patch of felodipine to avoid first pass metabolism and to study the effect of permeation enhancer in formulated patches. Methods: The patches were prepared using HPMC K100M, PVP and ethyl cellulose polymers in different ratios with incorporating 30% PEG-400 as plasticizer by solvent evaporation technique. The prepared patches were evaluated for their physicochemical characteristics and in-vitro drug release study. Penetration enhancing potential of oleic acid and eucalyptus oil was determined by incorporating in different concentration in optimized patch. Result and discussion: On the basis of ex-vivo study the formulation F9 (HPMC: PVP; 1:1) with oleic acid & eucalyptus oil (1:1) as penetration enhancer showed maximum release of 91.45% over 24hrs. The formulation F9 followed Higuchi matrix and non-Fickian diffusion transport. Skin irritation studies on two rabbits were found to be free of irritation.
INTRODUCTION
A recent approach of drug delivery is to deliver the drug into systemic circulation using skin as a site of application. Transdermal drug delivery (TDD) having potential to deliver the drug locally as well as systemically. It is gaining prominence over other forms of drug delivery because it offers a lot of advantages, including minimal trauma induction, avoid first pass metabolism, non-invasiveness, increased patient compliance, potential for continuous & controlled delivery. 1, 2 The goal of transdermal patch designing is to maximize the flux into systemic circulation and simultaneously minimize the dose of the drug. 3 Felodipine (dihydropyridine derivative) is a potent calcium channel blocker and used in the treatment of hypertension & angina pectoris. Felodipine effectively reduces blood pressure in hypertensive patients due to its vasodilatation effect on L-type calcium channels. 4, 5 Its absorption is 100 % but undergoes CYP-3A4 dependent first pass metabolism in the intestine and liver. Thus the oral bioavailability is only 15% and more than 99% bound to plasma proteins. One of the major drawbacks in therapeutic application & efficacy of felodipine is its very low aqueous solubility. About 70% of total administered dose is excreted out as metabolites in urine. The usual dose of felodipine is 5-10mg daily with a maximum dose of 20mg daily. It causes rapid drop in systemic blood pressure and reflux tachycardia. So to avoid such adverse events, it should be given in extended dosage form. 5, 6 Hence, transdermal drug delivery system is more suitable to avoid first pass metabolism, improve patient compliance, therapeutic efficacy, bioavailability and to reduce the frequency of dosing & its side effects.
MATERIALS AND METHODS Materials
Felodipine was received as a gift samples from Cipla limited Bangalore, HPMC K100M and ethyl cellulose obtained from Colorcon Asia pvt. Ltd., Goa. PVP purchased from hi-media pharma, Mumbai. PEG-400 purchased from S.D. Fine chemical Ltd., Mumbai. Other materials used in the study (oleic acid, eucalyptus oil, methanol, glycerol, potassium dihydrogen phosphate & sodium chloride etc.) were of analytical grade. Distilled water was used throughout the study. Albino rabbits were provided by KLE College of Pharmacy, Belgaum. All handling and care of animals were performed according to the approval of Institutional Animal Ethical Committee of KLE College of Pharmacy, Belgaum.
Investigation of Physicochemical Compatibility of Drug and Polymer
The physicochemical compatibility between felodipine and polymers used in the films was studied by using Fourier transform infrared (FTIR-200 spectrometer, Spectrum one Perkin Elmer, USA) spectroscopy. The infrared (IR) spectra were recorded using an FTIR by the KBr pellet method and spectra were recorded. The spectra obtained for felodipine, polymers, and physical mixtures of felodipine with polymers were compared.
Preparation of transdermal patch
Transdermal patches containing felodipine were prepared by the solvent evaporation technique in cylindrical glass molds. The backing membrane was cast by pouring a 2 % (w/v) polyvinyl alcohol (PVA) solution followed by drying at 60 °C for 8 hours. The drug reservoir was prepared by dissolving HPMC, PVP and EC in water and methanol. The ratios of polymers were varied for all the formulations keeping the total weight fixed at 350 mg. PEG-400 30% (w/w of dry polymer composition) was added as a plasticizer. Oleic acid and eucalyptus oil 10% were used as permeability enhances. The drug felodipine was added into the homogeneous dispersion with slow stirring in a magnetic stirrer. The dispersion was uniformly cast on a PVA backing membrane and dried at room temperature for 24 hours for solvent evaporation. The patches have been removed by peeling and cut into a square dimension of 2×2 cm (4 cm 2 ). Formulated patches were kept into desiccators for 2 days for further drying & rapped in aluminum foil, packed in self sealing covers. Composition of all formulation is given in table 1.
Characterization of prepared transdermal patches Physical appearance
All the formulated transdermal patches of Felodipine were visually inspected for colour, flexibility, homogeneity & smoothness.
Thickness
The thickness of the formulated patch was measured at 3 different places on a single patch using screw gauge and average thickness of three readings was calculated. Same procedure was applied for each formulation. 7, 8 
Folding endurance
The folding endurance was measured manually for the formulated patches. A strip of patch (2×2cm 2 ) was cut and repeatedly folded at the same place until it broke. The number of times the patch could be folded at the same place without breaking or cracking was observed.
8,9

Weight uniformity
To check weight uniformity, three patches from each formulation batch was randomly selected. Patches of 2×2cm 2 were weighed individually on digital balance and average weight of three patches was calculated. 
Tensile strength
The tensile strength and percent elongation of the prepared films were performed using a Universal strength testing machine (Hounsfield, slinfold, U.K.). It is consists of two load cell grips. The upper one was movable and lower one was fixed. The test patch of size (2 x 2cm 2 ) was fixed between these two cell grips and force was gradually applied till the patch broke. The tensile strength of patch was taken directly from the dial reading in kg. The tensile strength was calculated as; [11] [12] [13] [14] [15] Tensile strength = Tensile load at break/ cross sectional area
Percentage Moisture uptake
The patches were weighed accurately and placed in the desiccators containing saturated solution of aluminum chloride, keeping the humidity at 79.5 % R.H. inside the desiccators. After 3 days the films were taken out and weighed for the percentage moisture absorption. The moisture uptake of films was calculated using the formula: 7, 8 Percentage moisture content = Final weight -Initial weight x 100
Initial weight
Drug content determination
The patch (2×2cm 2 area) was cut in small pieces and transferred into 15 ml of methanol contained a graduated glass stoppered flask. The flask has shaken for 24 hrs continuously in a mechanical shaker. Then the solution was filtered and the residue was washed with suitable solvent. The filtrate was made up to 100 ml with solvent and the absorbance was measured using a UV spectrophotometer at 239 λ max.
8,10
Thumb tack test
It is a qualitative test applied for determination of adhesive property of patch. This is the ability of the polymer to adhere to substrate with minor contact pressure. The relative tack property is detected by pressing the thumb simply on the adhesive.
7,8,16
In-vitro Release Studies
In vitro drug release studies of transdermal patch was performed by using a modified Franz diffusion cell across a dialysis membrane in which phosphate buffer pH 7.4 was used as the in vitro study fluid in the receptor compartment. The polymeric film is placed on the dialysis membrane. The holder contains the dialysis membrane. The formulation is then placed on the receiver compartment of the modified diffusion cell containing phosphate buffer pH 7.4. The donor and receiver compartments have kept in immediate contact by wrapping parafilm at the junction. The temperature of the diffusion cell is maintained at 37 ± 0.5 0 c by a circulating water jacket. The whole assembly is kept on a magnetic stirrer, and the solution has kept in receiver compartment that was constantly and continuously stirred throughout the experiment using magnetic beads. The samples were withdrawn (1 mL each time) at different time intervals and an equal amount of phosphate buffer pH 7.4 was replaced each time. The intensities of the samples were measured spectrometrically.
7,12,13
Ex-Vivo Release Studies Preparation of skin
A full thickness of skin was excised from dorsal site of dead albino rat (150-200gm) and skin was washed with water. The fatty tissue layer was removed. The outer portion with hairs was applied with depilatory and allowed to dry. The hairs were scrubbed with the help of wet cotton and washed with normal saline solution. The skin was kept in phosphate buffer solution (pH-7.4) in refrigerator until skin was used for release study. Prior to use, the skin was allowed to equilibrate with room temperature. After that the skin was mounted between donor and receptor compartment of cell. The skin was clamped in such a way that the dermal side will be in contact with receptor medium. 8, 11, 13 
Methodology
Phosphate buffer pH 7.4 was used as receptor solution. The volume of Franz diffusion cell was 30 ml and temperature was maintained at 37 ± 1°C with the help of hot plate. The diffusion has been carried out for 24 hours and 1 ml sample was withdrawn at different time interval for a period of 24 hour. The same volume of phosphate buffer with pH 7.4 was added to receptor compartment to maintain sink conditions and the samples were analyzed at 239 nm.
13,14
Skin Irritation studies
To predict the compatibility between polymeric patch and skin, Draize test for skin irritation was performed. Skin irritation was performed on healthy rabbits (average weight: 1.5 to 2.5 kg). The dorsal surface (50 cm 2 ) of rabbit was cleaned, and the hair was removed by shaving. The skin was cleared with rectified spirit. Formalin solution (0.8%) was used as control. The optimized formulation was placed over the skin and was removed after 24 hours. The resulted skin reaction was checked for erythema. The degree of irritation is regularly assessed for a period of up to 14 days. 8, 11 Vol 5, Issue 09, 2015.
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Stability studies As per ICH guidelines, transdermal patches were subjected to accelerated stability studies. Optimized formulation was exposed to controlled temperature (40±2 °C) and relative humidity (75±5 % RH) for a period of 2 months in humidity control oven (Lab Control, Ajinkya IM 3500 Series, India). After 15, 30 and 60 days the samples were taken out and analyzed for Physical appearance, folding endurance and ex-vivo drug release.
14
RESULTS AND DISCUSSION Investigation of physicochemical compatibility of drug and polymers
The FT-IR spectra were carried out to study the compatibility of pure drug felodipine and the combination of felodipine with the HPMC, PVP and EC. Infrared spectra of pure drug felodipine and physical mixture of drug with HPMC & PVP are shown in figure 1& 2.
Physicochemical evaluations of formulated patches
The matrix-type transdermal patches containing felodipine were prepared using three different polymers-HPMC, PVP and EC in different ratios along with plasticizer (PEG-400) by solvent evaporation technique & water: methanol in 1:1 ratios used as solvent. The prepared six formulations were subjected to various physicochemical characteristics such as percent moisture content, thickness, weight uniformity, folding endurance and drug content & in-vitro release study.
Based on physicochemical properties & in-vitro study results, formulation F1 which containing HPMC K100 M along with PVP-30 in ratios 1:1 selected for further formulations by incorporating permeability enhancers. Then formulations F7, F8 & F9 were prepared using permeability enhancers (Oleic acid, Eucalyptus oil) in different ratios and ex-vivo drug release studies, in vivo irritation test and stability studies were performed. The compositions of all the formulations are showing in table 1. Patches formulated with single polymers were found to be sticky in nature and drug was non-uniformly distributed. But transdermal patches with combined polymers (HPMC: PVP) were white in color with homogeneous appearance and possessed uniform surface.
The thickness of the films was measured using screw gauge from three different places and average thickness was calculated. The thickness was varied from 0.217 mm to 0.243 mm (table 2).The minimum difference in values assumed that the process used for preparing the drug delivery system is capable of giving reproducible results. Thickness of the patch increases with increase in concentration of HPMC & followed by PVP. Patch formulated by incorporating eucalyptus oil showed higher thickness as compared to other formulations.
The tensile strength was determined using Hounse field Universal testing machine for the drug loaded patch. The tensile strength was found to be in the range of 0.169kg to 0.247kg. With the increase in HPMC concentration strength of patches also increased. Transdermal patches with permeability enhancers showed a little increment in tensile strength as compared to patches without permeability enhancers.
The moisture uptake was varied from 1.32% to 2.78%. The formulation F1 (HPMC: PVP; 1:1) showed highest moisture uptake 2.78% as compare to other formulations, due to hydrophilicity of polymers. The formulation F5 showed lowest percent moisture absorption than other formulations. This might be because of the low water permeability of ethyl cellulose polymer compare to HPMC & PVP (hydrophilic polymers) which showed higher rate of moisture absorption (table 2) .
The folding endurance was found to be in the range of 124 to 271as depicted in table 2. HPMC showed more flexibility as compare to PVP followed by ethyl cellulose. These data revealed that the patches containing HPMC: PVP have good mechanical strength as compared to the patches containing PVP: EC. On increasing the concentration of HPMC on constant concentration of PVP there was a little decrease in folding endurance.
Drug loaded patches (2×2cm 2 ) were tested for uniformity of weight. The weight variation in formulation F1 to F9 was found to be in the range of 57.91to 65.04 mg. On incorporating permeability enhancer weight of formulation also increased. This showed that all the formulations more or less were uniform and values for all the formulations are tabulated in the table 2. The drug content in the patches varied in the range 95.29% to 98.47%. The experiment was repeated three times to validate the result. It was clear that there was a proper distribution of Felodipine in the formulated patches. Hence it was concluded that drug was uniformly distributed in all the formulations. The values are given in the table 2.
It is the ability of the polymer to adhere to substrate with little contact pressure. The thumb is simply pressed on the adhesive and the relative tack property is detected. The formulations showed better adhesive properties. Results are tabulated in table 3. Release studies of six formulations of Felodipine transdermal patch was performed through dialysis membrane in phosphate buffer pH-7.4 as the diffusion medium, the total amount of drug release was observed at different time interval for a period of 24 hours. The drug release was found to be in the range of 55.89% to 70.06%. The formulation F1 (HPMC: PVP,1:1) showed maximum drug release for 24 hours up to 70.06% as compare to other formulations F2 to F6 i.e. 67.30%, 58.78%, 60.69%, 55.89% and 67.65% respectively and shown in figure 3 From these results of drug release, it is concluded that the drug release is better in hydrophilic polymers rather than hydrophilic: lipophilic polymers in different ratios. The formulations were aimed for sustained release.
Ex-vivo study was carried out using rat abdominal skin in Franz diffusion cell taking phosphate buffer (pH-7.4) as diffusion medium. The formulation F7 & F8 containing oleic acid & eucalyptus oil 10% respectively as permeability enhancer showed higher drug release 87.42% & 81.14% respectively up to24 hours as compared to 70.06% up to 24 hours without permeability enhancer. The formulation F9 containing Oleic acid: Eucalyptus oil (ratio 1:1) showed highest drug release for 24 hours up to 91.45%. The enhancement differences among these two enhancers may be due to their different physico-chemical properties and mechanisms of action. The percent drug release for formulations F7 to F9 are given in the figure 5. Comparative percent cumulative drug release from formulation F1 to F9 are shown in figure 7 .
To predict the compatibility between polymeric patch and skin Draize test for skin irritation was performed on two healthy rabbits (1.5-2.5kg). In this test drug free as well drug containing optimized patch (F9) was applied on dorsal surface of each rabbit. In this case there was no erythema while positive control showed clear erythema. This indicates skin compatibility with these polymers and permeability enhancer for topical application (table 6) .
The release profiles of felodipine from all the formulations were processed into graphs for comparison of different orders of drug release to understand the linear relationship, i.e., kinetic principles. Release kinetics of felodipine for the formulations F1, F2, F3, F7, F8 and F9 follow Higuchi matrix, because diffusion to be the predominant mechanism of drug release Formulations F4, F5 and F6 follow zero order. From the Koresmeyer Pappas equation the n-values were found to be more than 0.5 for all formulations. Therefore it shows that the release mechanism was non-fickian diffusion (table 5) .
In view of potential utility of the formulation, Optimized formulation F9 was exposed to controlled temperature (40±2 °C) and relative humidity (75±5 % RH) for a period of 60 days in humidity control oven (Lab Control, Ajinkya IM 3500 Series, India). Formulation F9 was subjected to drug content, folding endurance and % drug release studies after 15, 30 & 60 days. At the end of 60 days there were no significant change observed in all physicochemical parameters. It confirms that formulation F9 was stable at the end of 60 days (table 7). 
CONCLUSION
The prepared transdermal drug delivery system of Felodipine using different polymers such as HPMC, PVP & EC had shown good promising results for all the evaluated parameters. Based on the in-vitro drug release studies and ex-vivo drug release studies results, formulation F9 prepared using HPMC K100M and PVP in 1:1ratios along with oleic acid and Eucalyptus oil (1:1) as permeation enhancers showed best drug release. From these results, it was concluded that the present work was satisfactory for avoiding first pass metabolism thereby improving bioavailability of Felodipine by formulating transdermal patches.
